Autonomix Medical, Inc. announced on June 27, 2025, that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,279,889 B2. This patent, titled 'Systems and Methods for Neurological Traffic and/or Receptor Functional Evaluation and/or Modification,' relates to advanced systems for locating, monitoring, and mapping electrophysiological signals.
The patent covers the evaluation and modification of neurological traffic before, during, and after neuromodulation or denervation procedures. It explicitly includes tools for accessing small vessels and navigating to target areas to treat cancerous tumors and associated pain, reinforcing the company's focus on precision nerve-targeted treatments.
This new patent further strengthens Autonomix's growing global intellectual property portfolio, which now includes over 80 issued patents. The technology described is designed to treat conditions influenced by sympathetic nerve activity, such as renal denervation for hypertension, chronic pain syndromes, and cardiac modulation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.